These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia. Hassan YAM; Daud Ali M; Al-Eid RR; Al-Ghuraya FA; Essa Alqasimi Z; Ahmad A; Eltrafi Z; Ghosn SA Vaccine; 2022 Nov; 40(49):7087-7096. PubMed ID: 36404426 [TBL] [Abstract][Full Text] [Related]
7. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256 [TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090 [TBL] [Abstract][Full Text] [Related]
9. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ; Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136 [TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021. Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ; MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654 [TBL] [Abstract][Full Text] [Related]
11. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
12. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735 [TBL] [Abstract][Full Text] [Related]
13. Exacerbation of immune thrombocytopenia following initial and booster vaccination with Pfizer-BioNTech COVID-19 vaccine. Aharoni M; Leader A; Shochat T; Raanani P; Spectre G Platelets; 2022 Jul; 33(5):781-786. PubMed ID: 35536172 [TBL] [Abstract][Full Text] [Related]
14. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G Front Immunol; 2022; 13():863554. PubMed ID: 35711445 [TBL] [Abstract][Full Text] [Related]
15. The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021. Mbaeyi S; Oliver SE; Collins JP; Godfrey M; Goswami ND; Hadler SC; Jones J; Moline H; Moulia D; Reddy S; Schmit K; Wallace M; Chamberland M; Campos-Outcalt D; Morgan RL; Bell BP; Brooks O; Kotton C; Talbot HK; Lee G; Daley MF; Dooling K MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(44):1545-1552. PubMed ID: 34735422 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. Klein NP; Stockwell MS; Demarco M; Gaglani M; Kharbanda AB; Irving SA; Rao S; Grannis SJ; Dascomb K; Murthy K; Rowley EA; Dalton AF; DeSilva MB; Dixon BE; Natarajan K; Stenehjem E; Naleway AL; Lewis N; Ong TC; Patel P; Konatham D; Embi PJ; Reese SE; Han J; Grisel N; Goddard K; Barron MA; Dickerson M; Liao IC; Fadel WF; Yang DH; Arndorfer J; Fireman B; Griggs EP; Valvi NR; Hallowell C; Zerbo O; Reynolds S; Ferdinands J; Wondimu MH; Williams J; Bozio CH; Link-Gelles R; Azziz-Baumgartner E; Schrag SJ; Thompson MG; Verani JR MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):352-358. PubMed ID: 35239634 [TBL] [Abstract][Full Text] [Related]
17. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022. Fleming-Dutra KE; Wallace M; Moulia DL; Twentyman E; Roper LE; Hall E; Link-Gelles R; Godfrey M; Woodworth KR; Anderson TC; Rubis AB; Shanley E; Jones JM; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(26):859-868. PubMed ID: 35771731 [TBL] [Abstract][Full Text] [Related]
18. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021. Hause AM; Baggs J; Marquez P; Myers TR; Gee J; Su JR; Zhang B; Thompson D; Shimabukuro TT; Shay DK MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1755-1760. PubMed ID: 34968370 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022. Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708 [TBL] [Abstract][Full Text] [Related]
20. Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study. Andersson NW; Thiesson EM; Laursen MV; Mogensen SH; Kjær J; Hviid A BMJ; 2022 Jul; 378():e070483. PubMed ID: 35831006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]